Ticagrelor Dosing and Clinical Use
For acute coronary syndrome (ACS), administer ticagrelor with a 180 mg loading dose followed by 90 mg twice daily maintenance dosing, and ticagrelor is contraindicated in patients with prior intracranial hemorrhage or active bleeding. 1, 2
Loading and Maintenance Dosing
Standard ACS Dosing
- Loading dose: 180 mg orally (chewed if possible for faster onset)
- Maintenance dose: 90 mg orally twice daily
- Administer regardless of whether the patient is clopidogrel-naïve or pre-treated with clopidogrel 1, 2
- When switching from clopidogrel to ticagrelor, give the full 180 mg loading dose irrespective of clopidogrel timing or dose 1
Long-term Secondary Prevention Dosing
For stable patients ≥1 year post-MI at high risk for atherothrombotic events:
- Maintenance dose: 60 mg twice daily (no loading dose needed in this setting)
- Continue in combination with low-dose aspirin 75-100 mg daily 3
Aspirin Co-administration Requirements
Critical: Always use low-dose aspirin (75-100 mg daily) with ticagrelor, never high-dose aspirin. Post-hoc analysis of the PLATO trial demonstrated that aspirin doses >100 mg daily reduced ticagrelor's efficacy 2. The loading dose of aspirin should be 162-325 mg (chewed), followed by 75-100 mg daily maintenance 2.
Absolute Contraindications
Do not use ticagrelor in patients with:
- Prior intracranial hemorrhage 1
- Active pathological bleeding 1
- History of stroke or TIA (this applies specifically to prasugrel, not ticagrelor - see below for nuance) 2
- Concomitant use with strong CYP3A4 inhibitors (e.g., itraconazole, ketoconazole) 4
Important Nuance on Stroke History
While prasugrel is absolutely contraindicated in patients with prior stroke/TIA due to increased intracranial bleeding risk 2, ticagrelor can be used in stroke patients but requires careful consideration. The THALES trial demonstrated that ticagrelor plus aspirin reduced stroke recurrence in mild-to-moderate acute ischemic stroke (NIHSS ≤5) but increased severe bleeding (0.5% vs 0.1%) 5. This represents a risk-benefit calculation rather than an absolute contraindication.
Duration of Therapy
ACS Patients Post-PCI
- Standard duration: 12 months of dual antiplatelet therapy (DAPT) with ticagrelor plus aspirin 1, 2
- Exception: Discontinue earlier if excessive bleeding risk (e.g., PRECISE-DAPT score ≥25) 1
- Brief DAPT strategy: Recent evidence suggests 1-3 months DAPT followed by ticagrelor monotherapy may reduce bleeding without increasing ischemic events, though this is not yet standard guideline recommendation 6
Medically Managed ACS (No PCI)
Continue ticagrelor for 12 months unless bleeding risk outweighs ischemic benefit 1
Clinical Scenarios and Timing
STEMI with Primary PCI
Administer ticagrelor immediately (Class I recommendation) to reduce MACE and stent thrombosis 2
NSTE-ACS with Planned Invasive Strategy
- If angiography anticipated within 24 hours: Ticagrelor can be given but upstream treatment is not mandatory
- If angiography anticipated >24 hours: Upstream ticagrelor may be considered (Class IIb) 2
Pre-treatment Strategy
Pre-treatment with ticagrelor is recommended when coronary anatomy is known and PCI decision is made, and in all STEMI patients 1
Common Pitfalls and Adverse Effects
Bleeding Risk
Ticagrelor does not increase major bleeding compared to clopidogrel in ACS, but does increase minor bleeding and intracranial bleeding 5. Always co-prescribe a proton pump inhibitor (PPI) to reduce gastrointestinal bleeding 1.
Non-bleeding Adverse Effects
- Dyspnea: Occurs more frequently than with clopidogrel, usually mild and self-limited 7
- Ventricular pauses: More common than clopidogrel, typically asymptomatic 7
- Hypotension and nausea: Monitor during initiation 7
Drug Interactions
Absolutely avoid strong CYP3A4 inhibitors (itraconazole, ketoconazole, clarithromycin, ritonavir) as they dramatically increase ticagrelor levels and bleeding risk 4. Moderate CYP3A4 inhibitors require dose adjustment or alternative antiplatelet selection.
Perioperative Management
Do not discontinue DAPT within the first month after stent placement for elective non-cardiac surgery 1. Continue aspirin perioperatively if bleeding risk allows, and resume ticagrelor as soon as possible postoperatively 1. The reversible binding of ticagrelor (unlike clopidogrel's irreversible binding) may allow for more rapid surgical intervention after discontinuation, though specific timing recommendations vary by procedure urgency 7.
Special Populations
Asian Patients
Standard dosing applies, though some evidence suggests reduced maintenance doses (60 mg twice daily or even lower) may provide adequate platelet inhibition with improved safety in Asian populations 8. However, current guidelines do not recommend routine dose reduction based on ethnicity alone 1, 2.
Elderly and Low Body Weight
Unlike prasugrel (which requires dose reduction to 5 mg daily for age ≥75 years or weight <60 kg), ticagrelor dosing remains 90 mg twice daily regardless of age or weight 2.